2018
DOI: 10.1080/14760584.2018.1510775
|View full text |Cite
|
Sign up to set email alerts
|

Ebola virus – prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 17 publications
0
1
0
Order By: Relevance
“…MVA encoded VLP: Geovax and Bravovax (China) announced they would collaborate to create a modified Vaccinia ankara viruslike particles (MVA-VLP) vaccine candidate for COVID-19. This vaccine developed from a recombinant MVA-VLP and employed for Ebola virus [32,33].…”
Section: Vaccines In Research Stagementioning
confidence: 99%
“…MVA encoded VLP: Geovax and Bravovax (China) announced they would collaborate to create a modified Vaccinia ankara viruslike particles (MVA-VLP) vaccine candidate for COVID-19. This vaccine developed from a recombinant MVA-VLP and employed for Ebola virus [32,33].…”
Section: Vaccines In Research Stagementioning
confidence: 99%